clinical trial · NCT04280081
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Eli Lilly and Company·phase2·active not recruiting·n = 77
Solid TumorMedullary Thyroid CancerSelpercatinib
brief summary
The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
started
Mar 16, 2020
primary completion
Mar 25, 2021
completion
Nov 1, 2027
last updated
Apr 24, 2026
official title
A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol